Opdivo will help renal cell carcinoma market value to reach $3.6 billion by 2023; Report

27 April 2016
2019_biotech_test_vial_discovery_big

The market for renal cell carcinoma (RCC), a form of kidney cancer, is set to rise from $2.1 billion in 2013 to $3.6 billion by 2023, according to research and consulting firm GlobalData.

This represents a compound annual growth rate of 5.6%, the report states.

It predicts growth across the eight major markets of the USA, France, Germany, Italy, Spain, the UK, Japan, and China, and expects this to be driven by factors including the rapid uptake of immune checkpoint inhibitors and combination regimens.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology